From each FDA label

How common are GLP-1 injection site reactions?

Injection site reactions are in the main trial table of 2 labels. The highest rate printed is 13.9% on Saxenda 3 mg (10.5% on placebo) and the lowest 8% on Zepbound 15 mg (2% on placebo). Separate trials, so not a ranking. Byetta lists it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Rate against placebo

How often injection site reactions happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

MedicineDoseOn itOn placeboDifferenceLabel
Saxenda3 mg13.9%10.5%+3.4 pointsDailyMed
Zepbound15 mg8%2%+6 pointsDailyMed
Word for word

What each label says about injection site reactions

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • In clinical trials in adults for weight reduction, 1.4% of Wegovy-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation).

Label revised Jun 18, 2026. DailyMed

Ozempic

  • In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of Ozempic-treated patients.

Label revised Jun 1, 2026. DailyMed

Zepbound

  • In Zepbound-treated patients in a pool of Study 1 and 2, injection site reactions were more frequent in those with anti-tirzepatide antibodies (11.3%) compared to those who did not develop anti-tirzepatide antibodies (1%).

Label revised Aug 28, 2026. DailyMed

Mounjaro

  • In the pool of placebo-controlled trials in adults, injection site reactions were reported in 3.2% of Mounjaro-treated patients compared to 0.4% of placebo-treated patients.
  • In the pool of seven clinical trials, injection site reactions occurred in 119/2,570 (4.6%) of Mounjaro-treated adult patients with anti-tirzepatide antibodies and in 18/2,455 (0.7%) of Mounjaro-treated adult patients who did not develop anti-tirzepatide antibodies.
  • In the clinical trial in pediatric patients 10 years of age and older, injection site reactions occurred in 3/50 (6%) of Mounjaro-treated pediatric patients with anti-tirzepatide antibodies and in 0/43 (0%) of Mounjaro-treated pediatric patients who did not develop anti-tirzepatide antibodies.

Label revised Aug 27, 2026. DailyMed

Trulicity

  • In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of Trulicity-treated patients and in 0.0% of placebo-treated patients.
  • The safety profile in pediatric patients treated with Trulicity 0.75 mg and 1.5 mg subcutaneously once-weekly was consistent with that described above for adult patients with type 2 diabetes mellitus with the exception of injection site reactions.
  • In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the Trulicity 0.75 mg group, 3.8% (2 patients) in the Trulicity 1.5 mg group, and 2.0% (1 patient) in the placebo group.

Label revised Jun 16, 2026. DailyMed

Saxenda

  • The most common reactions, each reported by 1% to 2.5% of Saxenda-treated patients and more commonly than by placebo-treated patients, included erythema, pruritus, and rash at the injection site.
  • Presence of antibodies may be associated with a higher incidence of injection site reactions and reports of low blood glucose.

Label revised Feb 25, 2026. DailyMed

Victoza

  • Injection site reactions (e.g., injection site rash, erythema) were reported in approximately 2% of Victoza-treated adult patients in the five double-blind, glycemic control trials of at least 26 weeks duration.
  • Less than 0.2% of Victoza-treated patients discontinued due to injection site reactions.

Label revised Oct 14, 2025. DailyMed

Byetta

  • Chills (n=4) and injection-site reactions (n=2) occurred only in Byetta-treated patients.
  • The two patients who reported an injection-site reaction had high titers of antibodies to exenatide.

Label revised Sep 2, 2025. DailyMed

Rybelsus and Ozempic tablets, Foundayo: no finding on this in the sections read here.

Not from trials

Reports to FDA about injection site reactions

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
TrulicityInjection site pain: 9,978 · Bleeding at the injection site: 3,164 · Injection site bruising: 1,967 · Redness at the injection site: 1,642 · Itching at the injection site: 1,264 · Injection site swelling: 821 · Injection site reaction: 31487,279
MounjaroInjection site pain: 9,482 · Bleeding at the injection site: 3,632 · Redness at the injection site: 3,184 · Injection site bruising: 2,172 · Itching at the injection site: 1,732 · Injection site swelling: 1,037 · Injection site reaction: 90797,440
ZepboundInjection site pain: 5,130 · Redness at the injection site: 2,417 · Bleeding at the injection site: 1,906 · Injection site bruising: 1,768 · Itching at the injection site: 1,506 · Injection site reaction: 1,371 · Injection site swelling: 78680,835
ByettaInjection site pain: 2,042 · Injection site bruising: 1,857 · Bleeding at the injection site: 1,832 · Redness at the injection site: 535 · Itching at the injection site: 457 · Injection site swelling: 156 · Injection site reaction: 10052,087
OzempicInjection site pain: 1,058 · Injection site bruising: 388 · Bleeding at the injection site: 290 · Injection site swelling: 240 · Redness at the injection site: 228 · Itching at the injection site: 117 · Injection site reaction: 9570,863
VictozaInjection site pain: 810 · Redness at the injection site: 470 · Bleeding at the injection site: 365 · Itching at the injection site: 350 · Injection site reaction: 321 · Injection site bruising: 298 · Injection site swelling: 13441,462
WegovyInjection site pain: 681 · Bleeding at the injection site: 465 · Injection site bruising: 258 · Redness at the injection site: 142 · Injection site swelling: 107 · Injection site reaction: 71 · Itching at the injection site: 3025,993
SaxendaRedness at the injection site: 156 · Itching at the injection site: 131 · Injection site bruising: 114 · Injection site pain: 100 · Injection site reaction: 57 · Injection site swelling: 37 · Bleeding at the injection site: 207,270
Rybelsus and Ozempic tabletsInjection site pain: 44 · Injection site bruising: 11 · Itching at the injection site: 10 · Injection site swelling: 9 · Redness at the injection site: 6 · Bleeding at the injection site: 6 · Injection site reaction: 67,758

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Injection site reactions on a GLP-1: common questions

Which GLP-1 causes the most injection site reactions?

No trial here ranks them. By the rates each label prints, Saxenda 3 mg is highest at 13.9% (placebo 10.5%) and Zepbound 15 mg lowest at 8% (placebo 2%). These come from separate trials with different people and doses, so compare each to its own placebo group.

How common are Saxenda injection site reactions?

In its FDA label, 13.9% of people taking Saxenda 3 mg reported injection site reactions, against 10.5% on placebo.

How common are Zepbound injection site reactions?

In its FDA label, 8% of people taking Zepbound 15 mg reported injection site reactions, against 2% on placebo.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.